Liraglutide

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2010 Apr 2

PMID 20357801

Citations 58

Authors

Daniel J Drucker

Argyris Dritselis

Peter Kirkpatrick

Affiliations

Soon will be listed here.

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

Citing Articles

Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins.

Elsayed Y, Kuhl T, Imhof D J Pept Sci. 2025; 31(3):e70001.

PMID: 39921384 PMC: 11806371. DOI: 10.1002/psc.70001.

Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration.

Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y Pharmaceutics. 2024; 16(11).

PMID: 39598478 PMC: 11597531. DOI: 10.3390/pharmaceutics16111353.

Machine Learning-Based Plasma Metabolomics in Liraglutide-Treated Type 2 Diabetes Mellitus Patients and Diet-Induced Obese Mice.

Park S, Kim E Metabolites. 2024; 14(9).

PMID: 39330490 PMC: 11434292. DOI: 10.3390/metabo14090483.

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.

Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C Signal Transduct Target Ther. 2024; 9(1):234.

PMID: 39289339 PMC: 11408715. DOI: 10.1038/s41392-024-01931-z.

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.

Feng J, Jin T Med Rev (2021). 2024; 4(4):312-325.

PMID: 39135602 PMC: 11317081. DOI: 10.1515/mr-2024-0018.

References

Garber A, Henry R, Ratner R, Garcia-Hernandez P, Rodriguez-Pattzi H, Olvera-Alvarez I . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2008; 373(9662):473-81. DOI: 10.1016/S0140-6736(08)61246-5. View

Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 32(1):193-203. PMC: 2606813. DOI: 10.2337/dc08-9025. View

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

Knudsen L, Nielsen P, Huusfeldt P, Johansen N, Madsen K, Pedersen F . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43(9):1664-9. DOI: 10.1021/jm9909645. View

Knudsen L, Madsen L, Andersen S, Almholt K, DE Boer A, Drucker D . Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151(4):1473-86. DOI: 10.1210/en.2009-1272. View

Drucker D, Sherman S, Gorelick F, Bergenstal R, Sherwin R, Buse J . Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010; 33(2):428-33. PMC: 2809297. DOI: 10.2337/dc09-1499. View

Drucker D, Buse J, Taylor K, Kendall D, Trautmann M, Zhuang D . Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372(9645):1240-50. DOI: 10.1016/S0140-6736(08)61206-4. View

Buse J, Rosenstock J, Sesti G, Schmidt W, Montanya E, Brett J . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39-47. DOI: 10.1016/S0140-6736(09)60659-0. View

Lovshin J, Drucker D . Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009; 5(5):262-9. DOI: 10.1038/nrendo.2009.48. View

10.

Zinman B, Gerich J, Buse J, Lewin A, Schwartz S, Raskin P . Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009; 32(7):1224-30. PMC: 2699702. DOI: 10.2337/dc08-2124. View

11.

Ban K, Hui S, Drucker D, Husain M . Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens. 2010; 3(4):245-59. DOI: 10.1016/j.jash.2009.04.001. View

12.

Marre M, Shaw J, Brandle M, Bebakar W, Kamaruddin N, Strand J . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3):268-78. PMC: 2871176. DOI: 10.1111/j.1464-5491.2009.02666.x. View

13.

Bunck M, Diamant M, Corner A, Eliasson B, Malloy J, Shaginian R . One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009; 32(5):762-8. PMC: 2671094. DOI: 10.2337/dc08-1797. View

14.

Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha I . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2008; 32(1):84-90. PMC: 2606836. DOI: 10.2337/dc08-1355. View